21-Jul-2017 - Recipharm AB

Recipharm and LIDDS establish industrial manufacturing capabilities

Manufacturing line for prostate cancer product set up

Recipharm and LIDDS have together set up a manufacturing line for LIDDS’ novel prostate cancer drug, Liproca®Depot, at Recipharm in Solna, Sweden.

The manufacturing line is dedicated to the first product based on LIDDS’ innovative NanoZolid®technology. Clinical trial material has already been produced and the facility is ready for future commercial manufacturing of Liproca Depot or other pharmaceutical formulations based on the NanoZolid technology. The manufacturing line has been adapted for GMP production and is industrialised according to a unique process invented by LIDDS, involving the installation of novel equipment that is new to the pharmaceutical industry.

”We are proud of having reached this important milestone in the development of a new product allowing improved therapy for a serious disease. This has been achieved by the hard work and close collaboration of experts at both LIDDS and Recipharm. LIDDS is a very innovative company and it has been extremely rewarding to work with the team”, says Torkel Gren, General Manager of Recipharm’s facility in Solna.

”With the successful manufacturing performed at Recipharm, LIDDS can offer license agreements for Liproca Depot with the advantage of having validated production in place, saving both time and money for pharma companies. In addition, we now have an established manufacturing facility ready for other NanoZolid projects”, says Monica Wallter CEO of LIDDS.

Facts, background information, dossiers
  • license agreements
  • production
More about Recipharm
  • News

    Recipharm releases first serialised products to Europe

    Recipharm has released its first serialised products to Europe from its facilities in Lisbon, Portugal and Stockholm, Sweden. In 2016 Recipharm committed to invest 40 million euros in preparing its facilities for the European Falsified Medicines Directive (EU FMD). The release of its first ... more

    Sanofi and Recipharm announce transfer of Holmes Chapel Manufacturing site

    Recipharm and Sanofi announced today that they have signed an agreement to transfer the Holmes Chapel site from global healthcare leader, Sanofi, to leading pharmaceutical contract development and manufacturing organisation, Recipharm. “Holmes Chapel brings Recipharm an ideal opportunity to ... more

    Recipharm invests in Brexit preparations

    Recipharm has established a dedicated taskforce to manage the potential impact of Brexit on its organisation. With less than a year until the UK exits the European Union (EU), the Sweden headquartered global CDMO is focused on managing the transition with minimal impact to its operations an ... more

  • Companies

    Recipharm AB

    Recipharm is a leading contract development and manufacturing organisation based in Europe. The Company operates nine main manufacturing facilities in Sweden, France, the UK and Switzerland and is headquartered near Stockholm. Recipharm supplies the global pharmaceuticals market with in exc ... more